Selecta

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

News

Sobi plans filings for gout drug after phase 3 readout

SEL-212 will compete with Horizon's fast-growing Krystexxa if approved by the FDA.

News

Astellas licenses companion drug for Pompe gene therapy

Astellas has licensed rights to a drug developed by Selecta Biosciences that could make more patients eligible for treatment with its gene therapy for inherited neuromuscular disorder Pompe

News

Sarepta agree gene therapy R&D pact with Selecta

Rare disease specialist Sarepta Therapeutics has joined with Selecta Biosciences in a research pact to develop ways to allow its gene therapies to be re-dosed.

11 blockbuster drugs to look out for in 2025

Sobi plans filings for gout drug after phase 3 readout

Astellas licenses companion drug for Pompe gene therapy

Sarepta agree gene therapy R&D pact with Selecta

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Selecta

Editor's Picks